Chemokine Therapeutics Corp.

Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced that research results were presented yesterday by the laboratory of Dr.

Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted U.S. Patent No. 7,378,098. Patent No.

VANCOUVER, BRITISH COLUMBIA--(Marketwire - June 12, 2008) - Chemokine Therapeutics Corp.

Chemokine Therapeutics Corp. (the "Company") (TSX: CTI)(OTCBB: CHKT), a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders and vascular diseases, today announced that it has been granted two U.S. Patents (No's 7,354,899 and 7,368,425). Patent No.